Stealth BioTherapeutics (MITO) Announces FDA Grants Rare Pediatric Disease Designation for Elamipretide for Treatment of Barth Syndrome

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. SPCX
4. IBM
5. ACN
6. NVDA
7. PRIM
8. META
9. SPY
10. TSLA

Go back to Stealth BioTherapeutics (MITO) Announces FDA Grants Rare Pediatric Disease Designation for Elamipretide for Treatment of Barth Syndrome
(NASDAQ: MITO) Delayed: 0.32 --0 (-0%)
Previous Close $0.32    52 Week High $ 
Open $10.95    52 Week Low $ 
Day High $0.32    P/E N/A 
Day Low $0.32    EPS $ 
Volume 103,426